In your practice, how early do you recommend performing whole exome sequencing and in what tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?

Name: In your practice, how early do you recommend performing whole exome sequencing and in what tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?
Uploaded: 2017-09-26T00:00:00+00:00
Description: In your practice, how early do you recommend performing whole exome sequencing and in what types of tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?

CLICK HERE FOR CME CREDIT

Created by

Presenter

Jean-Charles Soria, MD

Professor of Medicine and Medical Oncology
South-Paris University
Cancer Specialist
Institut Gustave Roussy (IGR)
Paris, France

Related Videos

Video

What is the role of NGS-based molecular profiling for providing roadmaps suggesting how combination, targeted therapy can produce improved clinical outcomes?

Video

From a precision medicine perspective, how should we be integrating and incorporating ctDNA profiling — i.e., liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?

Video

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers ...

Video

Given some of the conflicting results reported by precision medicine trials, how do you reconcile some of the divergent results and their implications for NGS-based molecular stratification?